Articles by Josep M. Llovet, MD
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.